Dash Bio Raises $6.5M In Seed Financing
Dash Bio Raises $6.5M In Seed Financing
Despite tremendous innovation in biotech research over the past decade – from pioneering applications of AI to major breakthroughs in mRNA and CRISPR – drug development remains slow and expensive, with new drugs costing an average of Newly-unveiled startup to speed up biotech and drug development
新成立的初創企業將加快生物技術和藥物開發速度
NEWTON, Mass., Oct. 24, 2024 /PRNewswire/ -- Dash Bio, an innovator in tech-enabled services for drug development, announced today that it has raised $6.5M in seed financing. The round was led by Freestyle Capital, with participation from Swift Ventures, LifeX Ventures, and other private investors.
2024年10月24日，馬薩諸塞州Newton，/美通社/ -- 達世生物一家從事藥物開發科技服務的創新公司達世生物今天宣佈已獲得650萬美元的種子融資。本輪融資由Freestyle Capital領投，同時Swift Ventures、LifeX Ventures和其他私人投資者參與。
Dash Bio Launches with $6.5MM in Funding to Redefine Bioanalysis through technology and AI
達世生物以650萬美元的資金啓動，通過技術和人工智能重新定義生物分析
Despite tremendous innovation in biotech research over the past decade – from pioneering applications of AI to major breakthroughs in mRNA and CRISPR – drug development remains slow and expensive, with new drugs costing an average of $6.7 billion and taking 12 years to get from concept to launch. That lag is driven by manual processes and legacy systems, which dramatically reduce the efficiency of clinical development and the effectiveness of the industry overall.
儘管在過去10年間生物技術研究取得了巨大創新 -- 從人工智能的先導應用到mRNA和CRISPR的重大突破 -- 但藥物開發仍然緩慢且昂貴，新藥平均成本高達 $67億 並正在進行 12年 從概念板塊到推出產品需要時間。這種滯後是由手動流程和遺留系統驅動的，這大大降低了臨床開發的效率和行業整體的有效性。
"Development is broken in biotech today, and we all pay the price," says Dave Johnson, CEO and co-founder of Dash Bio and former Chief Data & AI Officer at Moderna. "We founded Dash Bio to ensure that groundbreaking medicines reach those who need them — faster."
「當今生物技術行業的發展出現問題，我們都爲此付出代價，」Dash Bio的首席執行官兼聯合創始人、現任Moderna公司的首席數據及人工智能官Dave Johnson表示。「我們創立Dash Bio是爲了確保開創性藥物能更快地到達需要的人群。」
Now out of stealth, Dash Bio takes a technology-first approach to developing critical services across the drug development lifecycle. The company is building new capabilities that leverage AI, robotics, and fully-integrated software to fundamentally reinvent the way drugs are brought to market. Their first capability is a highly-automated clinical bioanalysis lab that promises to deliver GLP-compliant services with unprecedented speed.
現在Dash Bio擺脫隱蔽狀態，採用技術爲先的方法來開發藥物開發生命週期的關鍵服務。該公司正在構建利用人工智能、機器人和全面集成軟件的新能力，從根本上改變藥物上市的方式。他們的第一個能力是一個高度自動化的臨床生物分析實驗室，承諾以前所未有的速度提供符合GLP標準的服務。
Dash Bio's founding team draws from a deep well of knowledge in this space. Founders include Dave Johnson (CEO), former Chief Data & AI Officer at Moderna; Ander Tallett (COO), CEO and founder of DigitalRadius and an experienced executive with stints at Moderna and Science Exchange; and Ely Porter, CTO and co-founder of Rootpath, a pioneer in synthetic immunology and gene synthesis.
Dash Bio的創始團隊汲取了這一領域豐富的知識。創始人包括Dave Johnson（首席執行官），他曾是Moderna公司的首席數據及人工智能官；Ander Tallett（首席運營官），DigitalRadius的首席執行官兼創始人，曾在Moderna和Science Exchange工作過；以及Ely Porter，Rootpath的首席技術官和聯合創始人，他是合成免疫學和基因合成領域的先驅。
"With the advancements of AI and quantum among other technologies, we are seeing huge advancements in drug discovery and expect that only to continue, but feel that the path from discovery through development to make drugs patient ready is still very antiquated and untouched by technology. We knew this was the team to tackle that challenge and you rarely find a team as deep in both AI and bio as this founding team," says Maria Palma, General Partner at Freestyle Capital.
「隨着人工智能和量子等其他技術的進步，我們看到藥物發現方面取得了巨大進展，並且預計這種進展將繼續下去，但我們認爲從發現到開發再到使藥物能夠接受患者的道路仍然非常過時，尚未受到技術的觸及。我們知道這支團隊是應對這一挑戰的最佳團隊，很少能找到像這樣既精通人工智能又擅長生物的團隊，」Freestyle Capital的普通合夥人Maria Palma表示。
"We're living through a golden age of biotech and drug discovery, but the reality is that the process for getting a drug to market threatens to slow progress. Dash Bio promises a new era of faster clinical drug development that meets the moment," notes Brett Wilson, General Partner at Swift Ventures.
我們正處在生物技術和藥物發現的黃金時代，但現實是，將藥物推向市場的過程可能會拖累進展。Dash Bio承諾開啓一個新時代，實現更快的臨床藥物開發，以滿足當下的需求。Swift Ventures的常務合夥人佈雷特·威爾遜指出。
About Dash Bio
Dash Bio is rebuilding drug development from the ground up by leveraging AI, robotics, and fully-integrated software to fundamentally reinvent the way drugs are brought to market. Learn more at dash.bio.
關於達世幣生物
達世幣生物正在通過利用人工智能、機器人和完全集成的軟件，從根本上重新構建藥物開發的方式，徹底改變推出市場的藥物方式。了解更多，請訪問 dash.bio.
SOURCE Dash Bio
資訊來源：達世幣生物
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎？
譯文內容由第三人軟體翻譯。
